← Back to Home

CLDN18.2 Antibody–Drug Conjugate Extends Survival in Advanced Gastric Cancer, Meets Dual Endpoints in Phase 3 Trial

In selected patients with gastric cancer who had received multiple lines of treatment, arcotatug tavatecan extended median overall survival from 6.9 to 10.2 months. The results support a marketing application in Japan, but nearly half of patients receiving the drug experienced grade 3 or higher treatment-related adverse events.

By SURL BioNews

When advanced gastric cancer continues to progress after several lines of treatment, whether the next drug can actually extend life often matters more than whether it shrinks tumors. Results from the phase 3 G-HOPE-001 trial, presented on October 23 at the European Society for Medical Oncology (ESMO) annual meeting, showed that the CLDN18.2-targeting antibody–drug conjugate arcotatug tavatecan improved both overall survival and progression-free survival in selected patients, adding new clinical evidence for later-line treatment.

The drug was developed by Innovent Biologics under the codes IBI343 and TAK-921; Takeda holds development and commercialization rights outside Greater China. It links an antibody that recognizes CLDN18.2 to the cytotoxic drug exatecan, delivering the drug through a marker on the tumor surface. This also makes pathology-based screening a prerequisite for the efficacy evidence: the trial required at least 75% of tumor cells to have CLDN18.2 staining intensity of 2+ or higher.

The study was conducted in China and Japan using a randomized, open-label design. According to OncLive's summary of the conference data, the analysis included 460 patients with HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who had received two to four lines of treatment, with 230 patients in each group. The control group received physician's choice of treatment, with 92.2% receiving irinotecan. The results therefore primarily reflect the new drug's performance relative to this type of later-line treatment and cannot be directly interpreted as showing superiority over all existing therapies.

At the second interim analysis, with a data cutoff of September 3, median overall survival was 10.2 months in the new-drug group and 6.9 months in the control group. The hazard ratio for death was 0.57, with a 95% confidence interval of 0.45 to 0.73, a statistically significant difference. This hazard ratio describes the relative risk of death between the two groups during follow-up; it does not mean that every patient gains a fixed number of months of life. OncLive also reported one-year survival rates of 43.2% and 24.7%, respectively.

Disease control showed a consistent direction of benefit, although the analysis time points must be distinguished. In the formal progression-free survival analysis at the first interim analysis, the medians were 5.5 months and 2.9 months; the descriptive update at the second analysis reported 7.1 months and 3.1 months. Takeda and Innovent reported confirmed objective response rates of 37.4% versus 7.7%. According to conference reporting, these response rates were calculated among patients with measurable lesions and indicate tumor shrinkage that meets assessment criteria, rather than a cure.

The improvement in efficacy was accompanied by substantial toxicity. Grade 3 or higher treatment-related adverse events occurred in 47.4% of patients, compared with 55.9% in the control group. When adverse events that emerged during treatment but were not necessarily attributable to the drug were included, the rates were 58.3% and 62.6%. More common high-grade events in the new-drug group included anemia and decreased blood cell counts. There was also one sudden death of unknown cause that was judged to be treatment-related. A lower overall rate does not mean that the treatment burden was mild.

Takeda said these data would support a marketing application in Japan. Innovent said the application in China had entered priority review, although that review designation does not itself constitute approval. The publicly available evidence currently comes mainly from conference presentations and corporate announcements, and the final overall survival analysis has yet to be completed. Given that the study was concentrated in China and Japan and used a defined biomarker threshold, these findings most directly support later-line patients who meet the trial criteria. The benefits and risks in broader populations remain to be clarified by further data.

References

  1. Takeda
  2. Innovent Biologics via PR Newswire
  3. OncLive